U.S. Markets open in 2 hrs 28 mins

Alexion Pharmaceuticals, Inc. (ALXN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
126.23+2.65 (+2.14%)
At close: 4:00PM EDT

126.50 0.27 (0.21%)
Pre-Market: 5:00AM EDT

People also watch
Full screen
Previous Close123.58
Bid124.31 x 100
Ask128.41 x 100
Day's Range124.01 - 126.68
52 Week Range96.18 - 145.42
Avg. Volume3,034,862
Market Cap28.35B
PE Ratio (TTM)60.14
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Biotech Insider Just Loaded Up $234 Million Worth the Stock

    Massive biotech bet!

  • Barrons.com2 days ago

    Amgen: In Defense of A Pipeline

    Critics complain that Amgen’s pipeline is bereft of exciting possibilities. Meanwhile, Amgen’s genetics-based R&D approach hasn’t delivered any homeruns yet, what with sputtering sales of its cholesterol drug Repatha and safety issues surrounding the experimental osteoporosis drug romosozumab.

  • Barrons.com3 days ago

    UPDATE: Alexion Pharma: Its CEO Really Likes Its Stock!

    For weeks, the news surrounding Alexion Pharmaceuticals (ALXN) has been all about the departures and arrivals in its executive suite. Today, the shares are up more than 3% on news that CEO Ludwig Hantson has recently purchased more than $1.1 million of the drug maker’s stock. A Form 4 filing with the SE showed that Hantson bought 10,000 shares of Alexion stock on June 14, a direct stock purchase that lifted his stake in the drug maker to 38,725 shares.